An article in the November issue of the American Journal of Medicine reports that a study of almost 400,000 COPD and asthma patients showed a 34% increase in the rate of Type 2 diabetes among those using inhaled corticosteroid (ICS). Higher doses of ICS were associated with higher increased risk of developing diabetes. The study was conducted by researchers from the Lady Davis Institute for Medical Research at Jewish General Hospital in Montreal, Canada. Read the abstract.
Study shows increased risk of diabetes with ICS use
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
